

BREAST

Open Access



AI software as a third reader in breast cancer screening—a prospective diagnostic observational study

Thomas Lehnen¹, Doris Polenske¹, Barbara Daria Wichtmann^{2,3} and Nils Christian Lehnen^{2*} 

Abstract

Objective Despite advances in mammography screening, some cancers remain undetected, prompting the evaluation of artificial intelligence (AI) as an independent third reader to reduce missed cancers.

Materials and methods In this prospective study, women eligible for the German Mammography Screening were enrolled at six sites belonging to one screening unit between August 2023 and February 2024. Each mammogram underwent double reading and was independently analyzed using Transpara, an AI-based detection software. Cases rated BI-RADS 4 or 5 by any reader or given a risk score of 10 by the software were reviewed in a consensus conference. Endpoints included: primary—cancer detection rate (CDR) and positive predictive values (PPV); secondary—analysis of cancers detected only by the software or missed by it.

Results 15,356 female participants (mean age 58.6 ± 5.6 years) were included. Overall, 115 breast cancers were detected (CDR triple reading: 0.75%; 95% CI: 0.62%, 0.90%). CDR of double reading and standalone AI was 0.68% (95% CI: 0.56, 0.83%) and 0.66% (95% CI: 0.54, 0.81%). Using Transpara as a third reader increased the detection rate by 9.5% (95% CI: 4.7%, 16.8%) compared to double reading ($p = 0.002$). The PPV for consensus-conference referrals was 5.1% (95% CI: 4.2%, 6.1%), lower than double reading 7.5% (95% CI: 6.2%, 9.0%; $p < 0.001$). For recalled cases, the PPV was 13.7% (95% CI: 11.5%, 16.2%) versus 15.2% (95% CI: 12.6%, 18.1%; $p < 0.001$). All nine invasive cancers detected solely by AI were Luminal-A-like cancers. Among 13 cancers missed by the software, four were triple-negative.

Conclusion Adding Transpara as an independent third reader improved detection rates, mainly by identifying additional Luminal-A-like cancers, and increased the workload to the consensus conference and the number of recalled cases.

Key Points

Question Does the integration of AI software as an independent third reader improve cancer detection rates in mammography screening without increasing false-positive findings and recall rates?

Findings AI as an independent third reader increased cancer detection by 9.5%, mainly identifying Luminal-A-like cancers, significantly decreasing the positive predictive values of cases referred to at the consensus conference and increasing the number of recalled cases.

Clinical relevance Using AI as an independent third reader enhances mammographic cancer detection by offering radiologists complementary sensitivity, especially for low-risk lesions. However, maintaining human readers is essential, as AI may miss aggressive subtypes like triple-negative breast cancers.

Keywords Mammography screening, Computer-assisted diagnosis, Double reading

*Correspondence:

Nils Christian Lehnen
nils.lehnen@ukbonn.de

Full list of author information is available at the end of the article




© The Author(s) 2026. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Graphical Abstract

AI software as a third reader in breast cancer screening – a prospective diagnostic observational study

Does the integration of AI software as an independent third reader improve cancer detection rates in mammography screening without increasing the rate of false positive findings?



AI as an independent third reader enhanced cancer detection at the cost of an increased workload to the consensus conference and an increased recall rate.

Eur Radiol (2026) Lehnen T, Polenske D, Wichtmann BD, Lehnen NC;
DOI: 10.1007/s00330-026-12359-0

EUROPEAN SOCIETY OF RADIOLOGY
European Radiology

Introduction

Breast cancer remains a leading cause of cancer-related morbidity and mortality in women [1, 2]. Mammography screening has reduced breast cancer mortality in many countries [3, 4]. Nevertheless, not all cancers are detected by screening: data from the German mammography program (2011–2016) reported detection rates of 69.9–71.7% [5], despite double reading to improve sensitivity while maintaining specificity. Transpara (ScreenPoint Medical), a convolutional neural network-based, FDA-approved and CE-marked AI software, correctly classifies most screen-detected and about half of interval cancers [6, 7]. In the Mammography Screening with Artificial Intelligence (MASAI) trial, the first randomized controlled trial implementing AI software to a mammography screening program, the software improved the cancer detection rate and reduced radiologists' workload, while maintaining stable recall and false-positive rates [8]. In MASAI, the software triaged exams to single reading (low/intermediate risk) or double reading (high risk) and provided decision support to radiologists. Other prospective studies evaluated AI as an independent third reader. In ScreenTrustCAD, Dembrower et al assessed double reading plus AI as an independent third reader, with radiologists

blinded to AI results. Examinations exceeding a predefined risk score entered the consensus conference even if not selected by radiologists. They found triple reading to be superior to conventional double reading in terms of cancer detection [9]. Ng et al prospectively implemented an AI software as an additional reader to standard double reading. In this AI-assisted workflow, cases that were classified as 'no recall' by both radiologists but flagged by the AI system were not discussed at the consensus conference; instead, they were reviewed separately by a single radiologist for potential recall. They found a 7% relative increase in cancer detection rate compared to standard double reading [10].

We hypothesized that AI, as an independent third reader, would improve sensitivity without increasing false-positive or recall rates. Additionally, we analyzed sensitivity differences between AI and human readers by tumor characteristics and prognostic subtype.

Materials and methods

Ethics approval

This prospective study was approved by the local ethics committee, and informed consent from the study participants was obtained prior to inclusion.

Study sample

Between August 2023 and February 2024, women eligible for the German Mammography Screening Program were consecutively enrolled at six sites of the authors' screening unit in this single-center, prospective study. The only inclusion criterion was screening eligibility; participants with incomplete data due to early termination were excluded.

AI software

Transpara (ScreenPoint Medical) is a convolutional neural network-based software assisting radiologists in detecting breast cancer on mammograms [11]. Detailed training data are proprietary; high-level information has been published. Version 1.7, trained on > 200,000 mammograms including > 10,000 biopsy-proven cancers and prior false negatives, assigns each exam a risk score from 1 to 10 (10 = highest risk). Suspicious regions are highlighted and scored 1–100, with values ≥ 60 yielding a risk score of 10. For this study, version 1.7.3 was used without recalibration. According to the manufacturer, it shares the same algorithm as version 1.7.0 used in the MASAI trial.

Study design

Two of ten certified screening radiologists independently read each 2D mammogram according to BI-RADS [12]. Examinations rated BI-RADS 4 or 5 by any reader were reviewed in a consensus meeting (two readers + one program director) to determine further work-up. Findings were classified as densities, microcalcifications, or architectural distortions. Spiculated margins or radiating lines without central masses were categorized as distortions. Each mammogram was also analyzed by the AI software, treated as an independent third reader. Cases with a risk score of 10 were added to the consensus meeting. Radiologists were blinded to AI results during primary reading but had access during consensus. Based on additional imaging or clinical results, participants underwent biopsy or routine follow-up after 2 years. A case was positive if cancer was histologically confirmed, and negative if no malignancy was found or no further work-up was recommended.

Primary endpoint

The primary endpoint was the cancer detection rate (CDR) and the positive predictive value (PPV) for consensus referrals and recalled cases of triple reading with AI as a third reader and conventional double reading.

Secondary endpoints

Secondary endpoints were (1) sensitivity differences between AI and an average reader for cancers detected only by AI or missed by it, stratified by key tumor

characteristics; (2) the effect of replacing one reader with AI on sensitivity.

PPV was defined as the proportion of cancers among consensus or recalled cases. Invasive cancers with positive hormone receptor, negative HER2, and Ki-67 < 20% were classified as Luminal-A-like; all others as non-Luminal-A-like [13].

Post hoc analysis

A post hoc analysis included score 9 densities but excluded score 10 cases based only on calcifications with regional scores < 75 to assess potential gain in detection versus workload, as no carcinomas were found among such score 10 cases. The process of inclusion and exclusion and the study design are summarized in Fig. 1.

Statistical analysis

Statistical analyses were conducted with R, version 4.4.1, and RStudio, version 2024.04.2 + 764. Confidence intervals for single proportions were calculated using the Clopper-Pearson method. Sensitivity differences between AI and the average reader were analyzed using a paired design. Fractional discordant counts from averaging across readers were rounded to the nearest whole number to match the overall true-positive difference. Ninety-five percent confidence intervals for paired sensitivity differences were calculated with DTComPair [14] using the Agresti–Min method, and group differences were assessed with McNemar's test or McNemar's exact test. For PPV analyses, the DTComPair package and the compbdt script were used [15]. For comparing PPV between the average reader-plus-AI and the three-reader strategy, a χ^2 test was applied. To control the family-wise error rate across the three primary hypotheses, a Bonferroni correction was applied, setting significance at $p = 0.0167$. Secondary and post hoc analyses were exploratory without correction for multiple testing; p -values are reported descriptively. ROC analysis was performed using software-provided risk scores and the pROC package [16]. No statistical power analysis was performed for this study.

Results

Study sample

Of 15,372 enrolled women, 16 (0.1%) were lost to follow-up and excluded, leaving 15,356 participants. Among them, 115 breast carcinomas (CDR triple reading: 0.75%; 95% CI: 0.62–0.90%) were diagnosed, including 99 invasive cancers. One lung cancer metastasis detected was not included in the final analysis. Baseline, screening, and tumor characteristics are summarized in Table 1.

Impact on detection rate and PPVs

The software's CDR was 0.66% (95% CI: 0.54–0.81%, 102/15356) with an AUC of 0.94 (95% CI: 0.92–0.96). Ten of




Fig. 1 Study design

Table 1 Screening results and tumor characteristics

Characteristic	Number	%	95% CI
Participants	15,356	100.0%	
Mean age (years)	58.6 ± 5.6		
BI-RADS 2, 3, B2, B3	15,240	99.24%	(99.1–99.4%)
Breast cancers	115	0.75%	(0.6–0.9%)
Metastasis	1	0.01%	(0.00–0.04%)
Breast cancers, histology confirmed, total	115	100.0%	(96.8–100.0%)
DCIS	16	13.9%	(8.2–21.6%)
Invasive, NST and not lobular	77	67.0%	(57.6–75.4%)
Invasive lobular	14	12.2%	(6.8–19.6%)
Invasive, mixed with lobular component	8	7.0%	(3.1–13.3%)
Invasive, immunohistochemical features, total	99	100.0%	(96.3–100.0%)
ER positive, HER2 negative, Ki-67 < 20%	59	59.6%	(49.3–69.3%)
ER positive, HER2 positive or negative, Ki-67 ≥ 20%	22	22.3%	(14.5–31.7%)
Her2 positive, ER negative	6	6.1%	(2.3–12.7%)
Triple negative	12	12.1%	(6.4–20.2%)
Invasive, grade (Nottingham scale), total	99	100.0%	(96.3–100.0%)
1	25	25.3%	(17.1–35.0%)
2	54	54.6%	(44.2–64.6%)
3	19	19.2%	(12.0–28.3%)
Not documented	1	1.0%	(0.0–5.5%)
Tumor stage TNM classification is (postoperative)	115	100.0%	(96.8–100.0%)
1a (postoperative)	16	13.9%	(8.2–21.6%)
1b (postoperative)	11	9.6%	(4.9–16.5%)
1c (postoperative or clinical)	28	24.3%	(16.8–33.2%)
2 (postoperative or clinical)	30	26.1%	(18.3–35.1%)
4 (postoperative or clinical)	12	10.4%	(5.5–17.5%)
1 (postoperative after neoadjuvant chemotherapy)	1	0.9%	(0.0–4.8%)
2 or 3 (postoperative after neoadjuvant chemotherapy)	12	10.4%	(5.5–17.5%)
Not documented	3	2.6%	(0.5–7.4%)
Nodal stage TNM classification	2	1.7%	(0.2–6.1%)
N0	99	100.0%	(96.3–100.0%)
N positive	82	82.8%	(74.0–89.7%)
Not documented	16	16.2%	(9.5–24.9%)
Not documented	1	1.0%	(0.0–5.5%)

BI-RADS Breast Imaging Reporting and Data System, B pathological grading system, DCIS ductal in situ carcinoma, NST not specified tumor, ER estrogen, HER2 human epidermal growth factor receptor 2, is in situ

115 cancers (8.7%; 95% CI: 4.2–15.4%) were detected solely by the software, increasing the detection rate by 9.5% (95% CI: 4.6–16.8%; $p = 0.002$) versus double reading (CDR double reading: 0.68%; 95% CI: 0.56–0.83%,

105/15356). Nine of these were invasive, and one was ductal carcinoma in situ (DCIS).

PPV for all consensus cases, including those selected by AI, was 5.1% (95% CI: 4.2–6.1%; 115/2264), 2.4 (95% CI: 2.0, 2.8) p.p. lower than with double reading (7.5%; 95% CI: 6.2–9.0%; 105/1403; $p < 0.001$, rPPV = 0.68 [95% CI: 0.64, 0.72]). PPV for recalled cases was 13.7% (95% CI: 11.5–16.2%, 115/838) for triple reading, 1.5 (95% CI: 0.7, 2.3) p.p. lower than the 15.2% for double reading (95% CI: 12.6–18.1%, 105/689; $p < 0.001$, rPPV = 0.9 [95% CI 0.85, 0.95]). Sensitivities and PPVs are summarized in Table 2; the ROC curve is shown in Fig. 2.

Sensitivity by tumor features: AI-only and AI-missed, compared with average reader

Cancers detected or missed by AI and their characteristics are listed in Table 3; corresponding sensitivities are shown in Table 4.

All invasive AI-only cancers showed a Luminal-A-like IHC profile. Sensitivity was higher for AI (89.8%; 95% CI: 79.2–96.2%, 53/59) than for the average reader (67.8%; 95% CI: 54.4–79.4%, 40/59; $p = 0.004$).

Four of nine invasive AI-only cancers (44.5%; 95% CI: 13.7–78.8%) showed pure lobular histology. AI sensitivity for lobular cancers (92.9%; 95% CI: 66.1–99.8%, 13/14) exceeded that of the average reader (50.0%; 95% CI: 23.0%; 77.0%, 7/14; $p = 0.016$). Invasive cancers detected only by AI appeared as architectural distortions ± densities, without microcalcifications, in 36.4% (95% CI: 26.9–46.6%, 36/99). For this pattern, AI sensitivity (91.7%; 95% CI: 77.5–98.2%, 33/36) exceeded that of the average reader (66.7%; 95% CI: 49.0–81.4%, 24/36; $p = 0.02$). Five of nine invasive AI-only cancers (55.6%; 95% CI: 21.2–86.3%) were small (pT1a/b). For T1a/b cancers, AI sensitivity (92.3%; 95% CI: 79.1–98.4%, 36/39) exceeded that of the average reader (71.8%; 95% CI: 55.1–85.0%, 28/39; $p = 0.04$).

13 of 115 (11.3%; 95% CI: 6.2–18.6%) cancers had a software score < 10 and were thus false negatives (Table 3). They comprised 2 DCIS and 11 invasive cancers; 5 (45.5%; 95% CI: 16.7–76.6%) were non-Luminal-A-like, including 4 triple-negatives. For these non-Luminal-A-like cancers, sensitivities did not differ between AI (87.5%; 95% CI: 73.2–95.8%) and the average reader (90.0%; 95% CI: 76.3–97.2%; $p = 0.70$). The three triple-negative cancers with scores < 9 showed high proliferation (Ki-67 ≥ 25%) and appeared as pure densities without calcifications or distortions. Among all pure-density cancers, sensitivities were similar for AI (82.9% [95% CI: 66.4%, 93.4%, 29/35]) and the average reader (80.0% [63.1%, 91.6%], 28/35; $p = 0.75$). Three non-Luminal-A-like cancers detected by AI would have been missed by the hypothetical average reader, and four vice versa.

Table 2 Sensitivities and PPVs of reading instances and reader combinations

	Sensitivity (% (95% CI), n/N)	PPV before consensus meeting (% (95% CI), n/N)	PPV recalled cases (% (95% CI), n/N)
2 readers + AI	100.0 (96.8–100), 115/115***	5.1 (4.2–6.1), 115/2264	13.7 (11.4–16.2), 115/838
2 readers	91.3 (84.6–95.8), 105/115	7.5 (6.2–9.0), 105/1403**	15.2 (12.6–18.1), 105/689**
1 reader + AI	96.5 (91.3–99.0), 111/115	6.0 (4.9–7.1), 110/1848	15.6 (13.0–18.5), 110/704
Reader (average of 10)	76.5 (67.7–83.9), 88/115	9.9 (8.0, 12.1), 88/887	17.8 (14.5–21.4), 88/494
AI	88.7 (81.4–93.8), 102/115	8.3 (6.9–10.0), 102/1223	24.1 (20.1–28.4), 102/424
AI modified*	93.0 (86.8–96.9), 107/115	6.1 (5.0–7.3), 107/1759	(Not applicable)

PPV positive predictive value, AI artificial intelligence

* Waiving lesions based on calcification findings with region scores < 75 while adding score 9 cases solely based on lesions classified by the AI as density (mass) or density/calcification for being presented in the consensus conference: Minimum values in case no additional cancers would be found

** Significant advantage compared to screening with AI as third reader

*** Significant advantage compared to double reading




Fig. 2 ROC curve of the software as an independent, single reader

Impact of replacing one reader with the software

Replacing one radiologist with AI yielded a sensitivity of 96.5% (95% CI: 91.3–99.0%, 111/115) compared with AI as a third reader ($p=0.063$; Table 2). Consequently, five cancers (4.3%; 95% CI: 1.4%, 9.9%) would have

been missed. The sensitivity difference from conventional double reading (91.3%, 95% CI: 84.6–95.8%, 105/115) was not significant ($p=0.3$). The 10 AI-only cancers would have been found at the expense of 4–5 missed cancers.

Table 3 Characteristics of cancers solely detected by AI and cancers missed by AI

AI score	ER status	HER2 status	Ki-67 (%)	T stage	G status	Histology (WHO)	Lesion consensus meeting (D, AD, C)	Lesion software (D, C)
10	Positive	-	-	is	2	DCIS	C	C
10	Positive	Negative	8	1c	2	Lobular	D	D
10	Positive	Negative	8	1c	2	Lobular	D, AD	D
10	Positive	Negative	8	1a	1	Mixed	AD	D
10	Positive	Negative	9	1b	2	NST	D, AD	D
10	Positive	Negative	12	1b	2	Lobular	AD	D
10	Positive	Negative	12	1a	1	Lobular	D, AD	D
10	Positive	Negative	13	1b	2	NST	D	D
10	Positive	Negative	15	y2	2	Lobular	AD	D
10	Positive	Negative	16	1c	2	mp	D	D
9	Positive	-	-	is	2	DCIS	C	C
2	Positive	-	-	is	1	DCIS	D	-
9	Positive	Negative	2	1c	1	NST	AD	D
9	Positive	Negative	3	1c	1	Lobular	C, D	C, D
9	Positive	Negative	3	1b	1	Tubular	AD	D
(10)*	Positive	Negative	3	1c	2	Mixed	AD	-
9	Positive	Negative	14	1c	2	NST	D	D
9	Positive	Negative	15	1c	2	NST	D	D
9	Positive	Positive	20	y0	3	NST	D	D
7	Negative	Negative	25	y1b	2	NST	D	-
9	Negative	Negative	28	1a/is	3	NST	C	C
2	Negative	Negative	35	1b	3	NST	D	-
6	Negative	Negative	40	1c	3	Metaplastic	D	-

All cancers in this table were nodal negative; 0* = score based on finding in the right breast, cancer of the left breast
 C: microcalcification; y: after neoadjuvant therapy; mixed: with lobular component; is: in situ; mp: micro papillary
 ER estrogen status, D density, mass, AD architectural distortion

PPV before the consensus meeting was 5.1% (95% CI: 4.2–6.1%; 115/2264) with AI as a third reader and 6.0% (95% CI: 4.9–7.1%; 110/1848) with one reader replaced. While screening with AI as a third reader yielded a higher number of positive assessments overall ($n = 2264$ vs. 1848), the number of true positives was similar (115 vs. 110, $p = 0.21$).

After consensus, PPV was 13.7% (95% CI: 11.5–16.2%; 115/838 recalls) with AI as a third reader and would have been 15.6% (95% CI: 13.0–18.5%; 110/704 recalls) with one reader replaced ($p = 0.32$).

Impact of adjustment of the software’s cutoff for cases referred to the consensus conference

Of seven invasive cancers with a lesion score of 9 (Table 3), six were classified by the software as densities. Only one AI-only cancer was based on microcalcifications (lesion score 77), identified as DCIS. Excluding score-10 cases with pure microcalcifications (lesion score < 75) and including score-9 cases containing densities would have yielded a sensitivity increase of the AI from 88.7% (95%

CI: 81.4–93.8%, 102/115) to 93.0% (95% CI: 86.8–96.9%, 107/115) and a pre-consensus PPV for AI cases of 6.1% (95% CI: 5.0–7.3%; 107/1759), assuming no additional cancers would have been found, 2.2 (95% CI: 1.8, 2.7) p lower than including all score 10 cases ($p < 0.001$, $rPPV = 0.73$ [95% CI: 0.68, 0.78]).

Examples of an AI-only cancer and two false-negative cases are shown in Figs. 3–5.

Discussion

In this prospective diagnostic study, AI as an independent third reader increased cancer detection compared with double reading, but also raised consensus workload and the number of recalled cases.

The present study included a limited number of pre-specified primary endpoints, for which the family-wise error rate was controlled using Bonferroni adjustment. In contrast, secondary and subgroup analyses were exploratory and not adjusted for multiplicity. Because of substantial subgroup overlap and interdependent diagnostic measures, a global correction would have been

Table 4 Sensitivities of the AI and the average human reader for various tumor characteristics

Cancer characteristics	Sensitivity AI (%)	Sensitivity reader (%)	Sensitivity difference	Sensitivity difference based on discordant cases, AI vs. average reader		p-value McNemar	Missed by AI, detected by reader (n)	Missed by reader, detected by AI (n)	Odds ratio	Advantage
	(95% CI), n/N	(95% CI), n/N	(% (95% CI))	Missed by AI, detected by reader (n)	Missed by reader, detected by AI (n)					
All breast cancers	88.7 (81.4–93.8), 102/115	75.7 (66.8–83.2), 87/115	13.0 (3.9–22.2)	8.5	23	0.01	8.5	23	0.4	AI
Luminal-A-like	89.8 (79.2–96.2), 53/59	67.8 (54.4–79.4), 40/59	22.0 (8.7–35.4)	3.5	16.5	0.004	3.5	16.5	0.2	AI
Non-Luminal-A-like	87.5 (73.2–95.8), 35/40	90.0 (76.3–97.2), 36/40	2.5 (–10.7–15.7)	4	3	0.7	4	3	1.3	AR
Invasive lobular	92.9 (66.1–99.8), 13/14	50.0 (23.0–77.0), 7/14	42.9 (16.2–69.6)	0	7	0.03	0	7	0	AI
Triple negative	66.7 (34.9–90.1), 8/12	88.3 (51.6–97.9), 10/12	16.7 (–13.7–47.1)	3	1	0.6	3	1	3	AR
T1a + T1b	92.3 (79.1–98.4), 36/39	71.8 (55.1–85.0), 28/39	20.5 (5.8–35.2)	1.5	9.5	0.04	1.5	9.5	0.1	AI
Distortion	91.7 (77.5–98.2), 33/36	66.7 (49.0–81.4), 24/36	25.0 (7.2–42.8)	2	11	0.02	2	11	0.2	AI
Density	82.9 (66.4–93.4), 29/35	80.0 (63.1–91.6), 28/35	28.6 (–19.6–13.9)	4.5	5.5	1	4.5	5.5	0.8	AI

Luminal-A-like: hormone receptor-positive plus Human Epidermal Growth Factor Receptor 2 negative plus cell proliferation marker (Ki-67) < 20%. Non-Luminal-A-like: all immunohistochemical features different from Luminal-A-like. Distortion: with or without density, without microcalcification; Density: without distortion, without microcalcification. AR: average from 10 human readers. All values were rounded to integer for McNemar tests

overly conservative. Therefore, secondary and post hoc results should be interpreted descriptively and considered hypothesis-generating rather than confirmatory.

The higher detection rate mainly resulted from a high sensitivity of the software for cancers with a Luminal-A-like risk profile according to IHC criteria. In contrast, AI-missed cancers were heterogeneous, including four triple-negative tumors—three with low software scores—all detected by double reading.

AI showed higher sensitivity for lobular histology, small tumors, and spiculations—features frequently associated with Luminal-A-like cancers. The previously reported high AI sensitivity in dense breasts [17] may explain its advantage for Luminal-A-like cancers, as architectural distortions and spiculations—linked to desmoplastic reactions—occur more often in slow-growing than in triple-negative cancers [18–22]. Sensitivity for lobular cancers likely depends on whether they induce architectural distortions. The predominance of Luminal-A-like cancers among AI-only detections may raise concerns of overdiagnosis of indolent tumors [23].

Our findings may inform optimal AI use. As detection reflects three independent readings with partly discordant true positives, removing one or more readers may reduce sensitivity. Alternative reading configurations were not evaluated, and any sensitivity–workload trade-off remains resource-dependent and requires prospective evaluation. Because AI gains were mainly driven by Luminal-A-like cancers, omitting a reader may risk missing non-Luminal-A-like, especially triple-negative, tumors. However, these findings of our study are descriptive in nature due to the low number of cases and are not supported by the current literature. In MASAI, omitting one reader for low-risk cases increased detection of both Luminal-A-like and non-Luminal-A-like cancers [8].

Including score-9 densities in consensus could further increase sensitivity and detection of invasive cancers. The additional workload might be offset by excluding cases with pure microcalcifications and lesion scores below 75.

Further improvements may come from context-driven approaches using asymmetries [24] or prior images [25].

A recent multicenter study found a 17.6% increase in detection when AI aided primary reading rather than acting as an independent third reader [26]. Our 9.5% improvement falls within the wide confidence interval (5.5–30%) of that study. In MASAI, the only randomized trial integrating AI into screening, Transpara was used both as a triage tool for single vs. double reading and as a radiologist support system [27]. Per-protocol analysis showed a moderate but significant increase in detection, with unchanged PPV and recall rates. Interestingly, the screen reading workload could be reduced by 44.2% in this setting [8]. Thus, AI triage and support reduced




Fig. 3 Case solely detected by AI: screening mammogram of a 69-year-old woman with a finding classified by AI as a mass (density), assigned a region score of 64 and a case score of 10. In the consensus conference, the finding was characterized as architectural distortion according to BI-RADS criteria. Histopathology confirmed a multifocal hormone receptor-positive invasive lobular carcinoma with a Ki-67 index of 15%. From left to right: Zoomed-in images of the mediolateral oblique (MLO) and craniocaudal (CC) views of the left breast screening mammogram, centered on the abnormality (arrowheads), with tomosynthesis views from additional imaging in the upper right corners, followed by the corresponding AI analysis and ultrasound correlate




Fig. 4 AI-negative case with an AI score just below the cutoff for presentation in the consensus conference. The finding was detected by one of the two human readers. The AI characterized it as a mass (density). During the consensus conference, it was characterized as an architectural distortion. Histopathological analysis confirmed a hormone receptor-positive tubular carcinoma with a Ki-67 index of 3%. Screening mammogram from a 64-year-old woman. From left to right: Zoomed-in images of the mediolateral oblique and craniocaudal views of the screening mammogram of the left breast, centered on the abnormality (arrowheads), with corresponding tomosynthesis views from additional imaging in the upper right corners, followed by the corresponding AI analysis and ultrasound




Fig. 5 AI-negative finding with a very low case score. The finding was detected by one of the two readers. A 65-year-old woman with a histopathological triple-negative breast cancer with a Ki-67 value of 35%. From left to right: zoomed-in views of the mediolateral oblique and craniocaudal screening mammograms, centered on the abnormality (arrowheads), with corresponding detail views from additional tomosynthesis in the upper right corners, followed by the AI analysis and a magnification view of the ultrasound. Clip marker on the craniocaudal tomosynthesis view

workload without lowering program sensitivity. In our study, Transpara as an independent third reader increased detection, but also consensus workload and the number of recalled cases. Thus, potential gains in cancer detection from using an AI as a third reader must be balanced against added workload and local resource constraints. Nonetheless, software may still serve as a compelling independent third reader: Knowing its results during primary reading can introduce bias [28], especially when low scores repeatedly occur in triple-negative cancers [28]. By contrast, in MASAI, the Transpara outputs were shown to radiologists to create a “beneficial bias,” reducing false positives in AI-low-risk cases and false negatives in AI-high-risk cases. The recall rate in the intervention group was numerically higher than in the control arm without statistical significance [8]. Furthermore, identifying cancers detected only by the software or missed by it enables cross-checking readers and software and supports cutoff fine-tuning, ideally in adequately powered studies. This level of review is not possible in randomized study designs. Finally, using this approach ensured that all participants benefited from the software.

To distinguish low- from high-risk cancers, tumors were classified as Luminal-A-like or non-Luminal-A-like. The 2021 St. Gallen Consensus defines Luminal A-like tumors as ER-positive, HER2-negative cancers with high PR expression and low Ki-67; no universal Ki-67 cutoff was agreed upon [13]. The proliferation marker Ki-67 has been extensively discussed for differentiating low and high-risk luminal cancers [29, 30]. In this study, we used a Ki-67 cutoff of 20%, acknowledging the inherent arbitrariness and inter-laboratory variability of this threshold. Recent research suggests a 22.5% cutoff for distinguishing between high and low-risk luminal cancers [31]. In our study, cancers classified as Luminal-A-like did not exceed a Ki-67 value of 17%. Additionally, cross-referencing with the Nottingham grading system revealed no non-Luminal-A-like cancers with G1 grading and no luminal-A-like cancers with G3 grading.

We acknowledge several limitations. First, although consensus decisions were based on BI-RADS criteria and context-driven case analysis, including prior images, a bias from the software score, known at this stage of screening, cannot be excluded. In simulating different reading scenarios, such as replacing one reader with the software, we averaged individual reader results—an unreal but pragmatic simplification. Although we assumed each reader worked independently of the software results, this assumption may not be fully true. During the consensus conference, all readers became aware of the software results, potentially introducing bias into subsequent readings. Furthermore, constructing a hypothetical average reader, as done here, did not readily permit statistical tests designed for paired data. Consequently, the PPV

comparison using χ^2 statistics does not fully account for the data’s paired nature, which should be considered when interpreting our results. Second, although our study took place within a single screening unit with six mammography units and ten qualified readers, it was not multicenter; thus, findings may not generalize to programs with different intervals, populations, technologies, AI systems, or workflows. Third, follow-up was insufficient to identify interval or next-round cancers, limiting ground truth to index-round, histologically verified cancers and potentially underestimating AI’s incremental value for cancers missed at initial double reading. Fourth, no prior power analysis was performed, leaving the study underpowered for reliable subgroup analyses. Thus, our subgroup findings are descriptive and must be interpreted cautiously. Still, we believe they are informative and may motivate future research with adequate power.

Using the software as an independent third reader maximized detection by leveraging the complementary strengths of human readers and software. Although sensitivity increased with an added AI reading instance, this required more consensus work and recalls and may be justifiable only where resources allow. We observed the higher detection rate mainly from the software’s higher sensitivity for low-grade invasive cancers. In contrast, detecting more high-risk cancers may depend on multiple independent readings that exploit discordances between readers and software. However, this latter finding requires further investigation in multicenter datasets and larger cohorts to enable meaningful subgroup analyses. Establishing meaningful benefit—beyond detection metrics—necessitates extended post-screening follow-up.

Abbreviations

AI	Artificial intelligence
CDR	Cancer detection rate
PPV	Positive predictive value
IHC	Immunohistochemistry
p.p.	Percentage points

Supplementary information

The online version contains supplementary material available at <https://doi.org/10.1007/s00330-026-12359-0>.

Acknowledgements

The authors would like to thank the radiologists involved in the double reading process and the consensus conference. We are also deeply grateful to Melanie Renken for her invaluable support in conducting this study.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Compliance with ethical standards

Guarantor

The scientific guarantor of this publication is Dr. Nils Christian Lehnen.

Conflict of interest

The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

Statistics and biometry

No complex statistical methods were necessary for this paper.

Informed consent

Written informed consent was obtained from all subjects (patients) in this study.

Ethical approval

Institutional Review Board approval was obtained.

Study subjects or cohorts overlap

There is no overlap of study subjects or cohorts with other publications.

Methodology

- Prospective
- Diagnostic study/observational
- Performed at one institution with six screening units

Author details

¹MVZ KERN Radiologie Lehnen/Polenske, Gelsenkirchen-Buer, Germany. ²Clinic for Neuroradiology, University of Bonn, University Hospital Bonn, Bonn, Germany. ³German Center for Neurodegenerative Diseases, Bonn, Germany.

Received: 1 June 2025 Revised: 27 December 2025 Accepted: 14 January 2026

Published online: 5 February 2026

References

- Arnold M, Morgan E, Rungay H et al (2022) Current and future burden of breast cancer: global statistics for 2020 and 2040. *Breast* 66:15–23
- Xu Y, Gong M, Wang Y, Yang Y, Liu S, Zeng Q (2023) Global trends and forecasts of breast cancer incidence and deaths. *Sci Data* 10:334
- Katalinic A, Eisemann N, Kraywinkel K, Nofzt MR, Hübner J (2020) Breast cancer incidence and mortality before and after implementation of the German mammography screening program. *Int J Cancer* 147:709–718
- Weigel S, Katalinic A (2024) Strukturierte Früherkennung des sporadischen mammarkarzinoms. *Radiologie* 64:463–470
- Heinze F, Czwikla J, Heinig M, Langner I, Haug U (2023) German mammography screening program: program sensitivity between 2010 and 2016 estimated based on German health claims data. *BMC Cancer* 23:852
- Bergan MB, Larsen M, Moshina N et al (2024) AI performance by mammographic density in a retrospective cohort study of 99,489 participants in BreastScreen Norway. *Eur Radiol* 34:6298–6308
- Lauritzen AD, Rodríguez-Ruiz A, von Euler-Chelpin MC et al (2022) An artificial intelligence-based mammography screening protocol for breast cancer: outcome and radiologist workload. *Radiology* 304:41–49
- Hernström V, Josefsson V, Sartor H et al (2025) Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI): a randomised, controlled, parallel-group, non-inferiority, single-blinded, screening accuracy study. *Lancet Digit Health* 7:e175–e183
- Dembrower K, Crippa A, Colón E, Eklund M, Strand F (2023) Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study. *Lancet Digit Health* 5:e703–e711
- Ng AY, Oberije CJG, Ambrózay É et al (2023) Prospective implementation of AI-assisted screen reading to improve early detection of breast cancer. *Nat Med* 29:3044–3049
- Screenpoint (2022) ScreenPoint Transpara User Manual: Softwareversion 1.7.3, SPM-MGR-009-014, Version B
- D'Orsi CJ, Sickles EA, Mendelson EB et al (2013) ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System, 5th edn American College of Radiology, Reston, VA
- Burstein HJ, Curigliano G, Thürlimann B et al (2021) Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. *Ann Oncol* 32:1216–1235
- Stock C, Hielscher T, Discacciati A (2024) DTComPair: comparison of binary diagnostic tests in a paired study design. R package version 1.2.6. <https://doi.org/10.32614/CRAN.package.DTComPair>
- Roldán-Nofuentes JA (2020) Compbdt: an R program to compare two binary diagnostic tests subject to a paired design. *BMC Med Res Methodol* 20:143
- Robin X, Turck N, Hainard A et al (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics* 12:77
- Koch HW, Larsen M, Bartsch H, Kurz KD, Hofvind S (2023) Artificial intelligence in BreastScreen Norway: a retrospective analysis of a cancer-enriched sample including 1254 breast cancer cases. *Eur Radiol* 33:3735–3743
- Sturesdotter L, Sandsveden M, Johnson K, Larsson A-M, Zackrisson S, Sartor H (2020) Mammographic tumour appearance is related to clinicopathological factors and surrogate molecular breast cancer subtype. *Sci Rep* 10:20814
- Franquet T, Miguel C, de Cozcolluela R, Donoso L (1993) Spiculated lesions of the breast: mammographic-pathologic correlation. *Radiographics* 13:841–852
- Boisserie-Lacroix M, Macgrogan G, Debled M et al (2013) Triple-negative breast cancers: associations between imaging and pathological findings for triple-negative tumors compared with hormone receptor-positive/human epidermal growth factor receptor-2-negative breast cancers. *Oncologist* 18:802–811
- Dogan BE, Turnbull LW (2012) Imaging of triple-negative breast cancer. *Ann Oncol* 23:vi23–vi29
- Gao B, Zhang H, Zhang S-D et al (2014) Mammographic and clinicopathological features of triple-negative breast cancer. *Br J Radiol* 87:20130496
- Ding L, Poelhekken K, Greuter MJW et al (2022) Overdiagnosis of invasive breast cancer in population-based breast cancer screening: a short- and long-term perspective. *Eur J Cancer* 173:1–9
- Wang X, Tan T, Gao Y et al (2023) DisAsymNet: disentanglement of asymmetrical abnormality on bilateral mammograms using self-adversarial learning. *arXiv:2307.02935*. <https://arxiv.org/pdf/2307.02935>
- Bai J, Jin A, Wang T, Yang C, Nabavi S (2022) Feature fusion Siamese network for breast cancer detection comparing current and prior mammograms. *Med Phys* 49:3654–3669
- Eisemann N, Bunk S, Mukama T et al (2025) Nationwide real-world implementation of AI for cancer detection in population-based mammography screening. *Nat Med* 31:917–924
- Lång K, Josefsson V, Larsson A-M et al (2023) Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study. *Lancet Oncol* 24:936–944
- Dratsch T, Chen X, Rezazade Mehrizi M et al (2023) Automation bias in mammography: the impact of artificial intelligence BI-RADS suggestions on reader performance. *Radiology* 307:e222176
- Li W, Lu N, Chen C, Lu X (2023) Identifying the optimal cutoff point of Ki-67 in breast cancer: a single-center experience. *J Int Med Res* 51:3000605231195468
- Petrelli F, Viale G, Cabiddu M, Barni S (2015) Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. *Breast Cancer Res Treat* 153:477–491
- Ma Q, Liu Y-B, She T, Liu X-L (2024) The role of Ki-67 in HR+/HER2- breast cancer: a real-world study of 956 patients. *Breast Cancer (Dove Med Press)* 16:117–126

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.